Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
IncelBull
IncelBull Aug. 6 at 1:59 PM
$LULU the LGBTQ community and women will need to downsize their yogapants after using pharmaceutical grade GLP-1s from companies such as $AZN $SNY $RHHBY $VKTX
1 · Reply
Makingmillions192
Makingmillions192 Aug. 6 at 10:04 AM
$LEXX Recent macro trends in the GLP-1 sector directly strengthen Lexaria’s strategic position: Medicare Coverage Expansion: CMS expanded its $50/month copay bridge program, driving retail channels to push lower-cost options. Capped reimbursements force Big Pharma to seek high-margin, scalable oral pills over expensive cold-chain injectables. Focus on Tolerability: Rapid oral market growth has shifted competition to patient adherence. DehydraTECH’s core value—reducing GI side effects and accelerating absorption—solves the primary cause of therapy discontinuation. (Inline with commentary following BIO convention) Persistent Supply Bottlenecks: Injectable autoinjector shortages remain a barrier, accelerating Big Pharma’s urgency to license proven oral drug-delivery platforms. There are so many companies that want in on this sector that could fast track years of R&D by buying or licensing Lexaria’s DHT tech. $LLY $NVO $RHHBY $VKTX
0 · Reply
scdtrader213
scdtrader213 Aug. 3 at 1:28 PM
$RHHBY slow and steady towards $60.00
0 · Reply
drdr3
drdr3 Aug. 2 at 2:12 AM
$MCRB $PFE RHHBY $RHHBY
0 · Reply
Quantumup
Quantumup Jul. 31 at 2:48 PM
BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20
0 · Reply
Tom2772
Tom2772 Jul. 30 at 7:30 PM
$OTLK $REGN $RHHBY You know what you own 💎 https://youtu.be/4t43-jAeJ6I?si=FAzfFL3tGRdp741N
1 · Reply
Quantumup
Quantumup Jul. 30 at 1:26 PM
Citizens⬆️ $LONA Market Outperform-$18 LLY $AZN $RHHBY NVS LLY PFE - ARVN CELC RLAY SNY BIIB IONS AMLX DNLI BIOA ELDN Here's what Citizens said in its upgrade: https://x.com/Quantumup1/status/2082819877786521646?s=20
0 · Reply
GreenEnergy7B
GreenEnergy7B Jul. 30 at 12:43 PM
$ALT The benefit of GLP1 Glucagon is in addition to weight loss - it is beneficial for MASH and or AUD patients $LLY $AZN $RHHBY $ABBV
0 · Reply
GoforProMIS
GoforProMIS Jul. 30 at 11:28 AM
$PMN is it $BIIB $LLY or is it $RHHBY for Alzheimer Disease ?
0 · Reply
Tom2772
Tom2772 Jul. 30 at 8:25 AM
$OTLK $REGN $RHHBY Actions speak louder than words. On July 29, Chairman Faisal G. Sukhtian bought 95,398 shares on the open market for nearly $100,000, increasing his direct holdings to 220,972 shares. I like seeing insiders buying after FDA approval, not selling.
0 · Reply
Latest News on RHHBY
No data available.
IncelBull
IncelBull Aug. 6 at 1:59 PM
$LULU the LGBTQ community and women will need to downsize their yogapants after using pharmaceutical grade GLP-1s from companies such as $AZN $SNY $RHHBY $VKTX
1 · Reply
Makingmillions192
Makingmillions192 Aug. 6 at 10:04 AM
$LEXX Recent macro trends in the GLP-1 sector directly strengthen Lexaria’s strategic position: Medicare Coverage Expansion: CMS expanded its $50/month copay bridge program, driving retail channels to push lower-cost options. Capped reimbursements force Big Pharma to seek high-margin, scalable oral pills over expensive cold-chain injectables. Focus on Tolerability: Rapid oral market growth has shifted competition to patient adherence. DehydraTECH’s core value—reducing GI side effects and accelerating absorption—solves the primary cause of therapy discontinuation. (Inline with commentary following BIO convention) Persistent Supply Bottlenecks: Injectable autoinjector shortages remain a barrier, accelerating Big Pharma’s urgency to license proven oral drug-delivery platforms. There are so many companies that want in on this sector that could fast track years of R&D by buying or licensing Lexaria’s DHT tech. $LLY $NVO $RHHBY $VKTX
0 · Reply
scdtrader213
scdtrader213 Aug. 3 at 1:28 PM
$RHHBY slow and steady towards $60.00
0 · Reply
drdr3
drdr3 Aug. 2 at 2:12 AM
$MCRB $PFE RHHBY $RHHBY
0 · Reply
Quantumup
Quantumup Jul. 31 at 2:48 PM
BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20
0 · Reply
Tom2772
Tom2772 Jul. 30 at 7:30 PM
$OTLK $REGN $RHHBY You know what you own 💎 https://youtu.be/4t43-jAeJ6I?si=FAzfFL3tGRdp741N
1 · Reply
Quantumup
Quantumup Jul. 30 at 1:26 PM
Citizens⬆️ $LONA Market Outperform-$18 LLY $AZN $RHHBY NVS LLY PFE - ARVN CELC RLAY SNY BIIB IONS AMLX DNLI BIOA ELDN Here's what Citizens said in its upgrade: https://x.com/Quantumup1/status/2082819877786521646?s=20
0 · Reply
GreenEnergy7B
GreenEnergy7B Jul. 30 at 12:43 PM
$ALT The benefit of GLP1 Glucagon is in addition to weight loss - it is beneficial for MASH and or AUD patients $LLY $AZN $RHHBY $ABBV
0 · Reply
GoforProMIS
GoforProMIS Jul. 30 at 11:28 AM
$PMN is it $BIIB $LLY or is it $RHHBY for Alzheimer Disease ?
0 · Reply
Tom2772
Tom2772 Jul. 30 at 8:25 AM
$OTLK $REGN $RHHBY Actions speak louder than words. On July 29, Chairman Faisal G. Sukhtian bought 95,398 shares on the open market for nearly $100,000, increasing his direct holdings to 220,972 shares. I like seeing insiders buying after FDA approval, not selling.
0 · Reply
Tom2772
Tom2772 Jul. 30 at 3:49 AM
$OTLK $RHHBY $PFIZER.NSE Thanks, guys. You're right! I need to correct myself. Faisal G. Sukhtian is the Chairman of the Board, not the CFO. That said, it doesn't change the point of my post. I still view the Chairman's insider purchase of around $100,000 as a positive signal.
0 · Reply
Tom2772
Tom2772 Jul. 29 at 8:06 PM
$OTLK $RHHBY $PFIZER.NSE "I like it when management has skin in the game." — Warren Buffett Another positive insider signal: CFO Sukhtian Faisal Ghiath acquired 95,398 shares at $1.0482 per share and now directly owns 220,972 shares.
0 · Reply
Quantumup
Quantumup Jul. 29 at 12:11 PM
Wells Fargo⬆️ $CLDX's PT to $72 from $48,⬆️barzolvolimab's estimates, and reiterated an Overweight rating. $NVS - $RHHBY SNY REGN Wells Fargo said -- While the St is modeling a high probability of success (PoS) for barzolvolimab's Ph3 in chronic spontaneous urticaria (CSU), it under-appreciates its commercial opportunity and potential early-line utilization due to overstated concerns around monitoring requirements and safety.
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 4:27 PM
$PMN either $LLY , $BIIB or $RHHBY will have to buy ProMIS otherwise each of them is going to lose at least $7-10 bn of the fast growing Alzheimer market. Presentation of today https://d1io3yog0oux5.cloudfront.net/_a52bc4a1574a61db158bebe9c6f0d9df/promisneurosciences/db/933/8992/pdf/Confidential+and+Final+-+PRECISE-AD+Interim+Results+Presentation.pdf
1 · Reply
Quantumup
Quantumup Jul. 27 at 2:17 PM
BRiley⬆️ $TGTX to $86 from $55 and reiterated Buy on strong Briumvi demand, likely quarterly revenue upside, and the potential for a 2028 subQ launch that could significantly expand the addressable market and drive long-term sales growth. $RHHBY $NVS BIIB
0 · Reply
scdtrader213
scdtrader213 Jul. 27 at 1:13 PM
$RHHBY moving towards $60
0 · Reply
fda_tracker
fda_tracker Jul. 24 at 2:30 PM
$RHHBY New PDUFA Date 2026-11-30 F. Hoffmann-La Roche Ltd Link: https://www.globenewswire.com/news-release/2026/07/23/3331865/0/en/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-strong-momentum-continues-in-the-first-half-of-2026-delivering-6-sales-growth-at-constant-exchange-rates-2-in-chf-due-to-the-signi.html Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
GoforProMIS
GoforProMIS Jul. 24 at 2:24 PM
$PMN just in case and saying keep an eye on ProMIS Neurosciences $LLY $BIIB $RHHBY
0 · Reply
scdtrader213
scdtrader213 Jul. 24 at 11:17 AM
$RHHBY Roche may have scrapped work on a T-cell engager (TCE) for lupus, but the company’s head of pharma told Fierce that the drugmaker still has a strategy for developing cell therapies for autoimmune diseases.
0 · Reply
Jumpman23
Jumpman23 Jul. 23 at 10:37 PM
$RHHBY above $54, ha. Finally. $VXUS should move up soon.
0 · Reply
scdtrader213
scdtrader213 Jul. 23 at 6:57 PM
$RHHBY finally moving towards 60
0 · Reply
induscapital
induscapital Jul. 23 at 4:34 PM
$TGTX So $RHHBY is giving away market share to $NVS and TGTX in U.S. market it seems for SC and IV section
0 · Reply